Targeted Protein Degradation Market By Technology (Proteolysis-Targeting Chimeras, Molecular Glues, Lysosome Targeting Chimeras, Others), By Application (Oncology, Neurodegenerative Diseases, Autoimmune Disorders, Infectious Diseases, Others), By Drug Type (Small Molecule-based Degraders, Biologic-based Degraders), By Route of Administration (Oral, Injectable), By End-user (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Contract Research Organizations, Others), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

---

Report Coverage:

By Technology

• Proteolysis-Targeting Chimeras
• Molecular Glues
• Lysosome Targeting Chimeras
• Others

By Application

• Oncology
• Neurodegenerative Diseases
• Autoimmune Disorders
• Infectious Diseases
• Others

By Drug Type

• Small Molecule-based Degraders
• Biologically based Degraders

By Route of Administration

• Oral
• Injectable

By End-user

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Contract Research Organizations
• Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Arvinas, Inc.
• C4 Therapeutics
• Nurix Therapeutics
• Kymera Therapeutics
• Monte Rosa Therapeutics
• Vividion Therapeutics
• Bristol Myers Squibb
• Roche Holding AG
• Pfizer Inc.
• Amgen Inc.
• Merck & Co., Inc.
• Novartis AG
• Foghorn Therapeutics
• Captor Therapeutics
• BioTheryX